Similarly, antibodies for IL-1β, which have been approved for the treatment of neurodegenerative diseases, have demonstrated significant individual differences in efficacy, and long-term safety has not been fully verified [208], weakening their potential for clinical use. Here, IL1B is linked to neurodegenerative disease.